Casselman J - Search Results

1

[Malignant adrenal gland tumors. A case report and an overview of the literature].

Adams T, Mattelaer P, Casselman J. Adams T, et al. Among authors: casselman j. Acta Urol Belg. 2000 Nov;68(3):50-2. Acta Urol Belg. 2000. PMID: 11678072 Review. Dutch. No abstract available.

2

Malignant melanoma of the glans penis.

Casselman J, Maes D. Casselman J, et al. Acta Urol Belg. 1987;55(3):467-71. Acta Urol Belg. 1987. PMID: 3661325 No abstract available.

3

PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.

Oosterlinck W, Mattelaer J, Casselman J, Van Velthoven R, Derde MP, Kaufman L. Oosterlinck W, et al. Among authors: casselman j. Acta Urol Belg. 1997 Oct;65(3):63-71. Acta Urol Belg. 1997. PMID: 9421938 Clinical Trial.

4

[Requirements for accreditation or retention of accreditation].

Casselman J. Casselman J. Acta Urol Belg. 1999;67(1):30-2. Acta Urol Belg. 1999. PMID: 10859820 Dutch. No abstract available.

5

A reno-gastric fistula.

Casselman J, Maes D. Casselman J, et al. Acta Urol Belg. 1988;56(1):10-2. Acta Urol Belg. 1988. PMID: 3364314 No abstract available.

6

Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients. A Belgian multicenter study of 905 patients.

Oosterlinck W, Casselman J, Mattelaer J, Van Velthoven R, Kurjatkin O, Schulman C. Oosterlinck W, et al. Among authors: casselman j. Eur Urol. 1996;30(4):458-63. doi: 10.1159/000474215. Eur Urol. 1996. PMID: 8977067 Clinical Trial.

7

Experience with percutaneous stone manipulation. Comparison between early and later results.

Oosterlinck W, Fonteyne E, Casselman J, Morelle V, Minnaert H, De Sy WA. Oosterlinck W, et al. Among authors: casselman j. Acta Urol Belg. 1985;53(3):501-6. Acta Urol Belg. 1985. PMID: 4061189 No abstract available.

8

Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer.

Vandenbroucke F, Van Poppel H, Derluyn J, Popelier G, Casselman J, Billiet I, Vanuytsel L, Paridaens R, Baert L. Vandenbroucke F, et al. Among authors: casselman j. Am J Clin Oncol. 1995 Jun;18(3):263-6. doi: 10.1097/00000421-199506000-00015. Am J Clin Oncol. 1995. PMID: 7747716 Clinical Trial.

9

Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial.

Boel K, Van Poppel H, Goethuys H, Derluyn J, Vandenbroucke F, Popelier G, Casselman J, Billiet I, Vanuytsel L, Paridaens R, Baert L. Boel K, et al. Among authors: casselman j. Anticancer Res. 1999 May-Jun;19(3B):2157-61. Anticancer Res. 1999. PMID: 10472324 Clinical Trial.

10

Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).

Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, Knönagel H, Loidl W, Isorna S, Sundaram SK, Debois M; EORTC Genitourinary Group. Studer UE, et al. Among authors: casselman j. Eur Urol. 2008 May;53(5):941-9. doi: 10.1016/j.eururo.2007.12.032. Epub 2007 Dec 27. Eur Urol. 2008. PMID: 18191322 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

294 results

Search Page

Filters